LB Pharmaceuticals names Joseph Miller chief financial officer, effective September 2
LB Pharmaceuticals appointed Joseph Miller as chief financial officer, effective September 2, 2026, replacing no named predecessor in the filing. Miller previously served as CFO of Aurinia Pharmaceuticals from April 2020 to March 2026, and the filing states his employment agreement sets a $530,000 base salary and a 40% target bonus, along with a 200,000-share stock option.
Key points
- Start date: September 2, 2026; announced September 3, 2026
- Base salary $530,000; target bonus 40% of base salary; employment is at will
- Inducement option for 200,000 shares of common stock, vesting over four years with 25% after the first anniversary of the start date
- Severance: nine months of base salary if terminated without cause outside a change of control; larger package of one year base salary plus 150% of target bonus within 3 months before or 12 months after a change of control
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.